Emerging Science, Emerging Ethical Issues: Who Should Fund Innate Alloimmunity-suppressing Drugs ?

References

• Akira S. TLR-signaling. Curr Top Microbiol Immunol, 2006, 311: 1.
   Google Scholar
• Munz Ch., Steinman R. M., Fujii S.-I. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Ex Med, 2005, 202: 203.
   Google Scholar
• Jayasekera J. P., Moseman E. A., Carroll M. C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol, 2007, 81: 3487.
   Google Scholar
• Land W. G. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation, 2005, 79: 505.
   Google Scholar
• Mahnke K., Enk A. H. Dendritic cells: key cells for the induction of regulatory T cells ? Curr Top Microbiol Immunol, 2005, 293: 133.
   Google Scholar
• Tan P. H., Sagoo P, Chan C. et al. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol, 2005, 174: 7633.
   Google Scholar
• Walsh M. C., Bourcier T., Takahashi K. et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol, 2005, 175: 541.
   Google Scholar
• Zhang M., Austen W. G. Jr., Chiù I. et al. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA, 2004, 101: 3886.
   Google Scholar
• Land W. G. Immunosuppressive strategies in organ transplantation in the light of innate immunity. Exp Clin Transplant, 2006, 4: 406.
   Google Scholar
• Land W. G. Innate immunity mediated allograft rejection and strategies to prevent it. Transplant Proc, 2007, 39: 667.
   Google Scholar
• Edaravone acute infarction study group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis, 2003, 15: 222.
   Google Scholar
• Cao C. X., Yang Q. W., Lv F. L., et al. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Comm, 2007, 353: 509.
   Google Scholar
• Land W., Schneeberger H., Schleibner S. et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation, 1994, 57: 211.
   Google Scholar
• Keshavjee S., Davis R. D., Zamora M. R. et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg, 2005, 129: 423.
   Google Scholar
• Kaden J., Strobelt V., May G. Short and long-term results after pretransplant high-dose single ATG-Fresenius bolus in cadaveric kidney transplantation. Transplant Proc, 1998, 30: 4011.
   Google Scholar
• Tahara M., Nakayama M., Jin M. B. et al. A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation. Transplantation, 2005, 80: 213.
   Google Scholar
• Masini E., Cuzzocrea S., Mazzon E. et al. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol, 2002, 136: 905.
   Google Scholar
• Zhang X., Vladau C., Feng B. et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. WTC-Congress Boston, abstract #711. Am J Transplant (Supplement), 2006, p. 307.
   Google Scholar
• Fire A., Xu S., Montgomery M. K. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391: 806.
   Google Scholar
• McKay D., Shigeoka A., Rubinstein M., Surh Ch., Sprent J. Simultaneous deletion of MyD88 and Trif delays major histocom-patibility and minor antigen mismatch allograft rejection. Eur J Immunol, 2006, 36: 1994.
   Google Scholar
• Lí M., Zhang X., Zheng X. et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells. WTC-Congress Boston, abstract# 725. Am J Transplant (Supplement), 2006, p. 311.
   Google Scholar
• Ondiveeran H. K., Fox-Robichaud A. Drug evaluation E-5564. IDrugs, 2004, 7: 582.
   Google Scholar
• Mahaffey K. W., van de Werf F., Shernan S. K. et al. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systemic overview. Am Heart J, 2006, 152: 291.
   Google Scholar
• Trouiller P., Torreele E., Olliaro P. et al. Drugs for neglected diseases: a failure of the market and a public health failure ? Trop Med Int Health, 2001, 6: 945.
   Google Scholar
• Wastfelt M., Fadeel B., Henter J. I. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med, 2006, 260: 1.
   Google Scholar
• Angell M. Excess in the pharmaceutical industry. CMAJ, 2004, 171: 1451.
   Google Scholar
• Barton J. H., Emanuel E. J. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA, 2005, 294: 2075.
   Google Scholar
• Bobrow M., Thomas S. Patents in a genetic age. Nature, 2001, 409: 763.
   Google Scholar
• Valverde J. L. (Ed). The European Regulation on Orphan Medicinal Products. Vol. 3: Pharmaceuticals Policy and Law. Amsterdam, The Netherlands: IOS Press, 2001.
   Google Scholar
• Fischer A., Borensztein P., Roussel C. The European rare diseases therapeutic initiative. PLoS Med, 2005, 2: e243.
   Google Scholar
• Brody B. A. Ethical issues in clinical trials in developing countries. Stat Med, 2002, 21: 2853.
   Google Scholar
• Hayasaka E. Approaches vary for clinical trials in developing countries. J Natl Cancer Inst, 2005, 97: 1401.
   Google Scholar
• Olliaro P., Smith P. G. The European and developing countries clinical trials partnership. J HIV Ther, 2004, 9: 53.
   Google Scholar
• Wheeler C., Berkley S. Initial lessons from public-private partnerships in drug and vaccine development. Bull World Health Organ, 2001, 79: 728.
   Google Scholar
• Demotes-Mainard J., Canet E., Segard L. Public-private partnership models in France and in Europe. Therapie, 2006, 61: 325334, 313.
   Google Scholar